United Therapeutics

The United Therapeutics product portfolio addresses the critical and unmet needs of patients with rare diseases and end-stage lung diseases. With a foundational focus on vascular conditions, the majority of our therapies are concentrated in Pulmonary Arterial Hypertension (PAH; Group 1) and Pulmonary Hypertension-Associated with Interstitial Lung Disease (PH-ILD; Group 3). Our goal is to reduce the progression of, and ultimately put an end to, end-stage organ disease through our organ manufacturing programs. Our product offerings have also expanded into the field of pediatric oncology with a therapy approved to treat high-risk neuroblastoma as part of United Therapeutics’ commitment to improving the lives of those living with orphan diseases.